How effective is Acyclovir for Planná Pox?

The use of acycloviru for falsexides is effective in most patients, although in many cases the use of the drug is not necessary. Research on the effects of treatment has shown that up to 95 percent of patients treated with acyclovir have ceased to develop characteristic lesions associated with falsepox about four days after the start of treatment. On the other hand, from subjects who received placebo treatment, only about 20 percent developed after six days.

Passpop Passport is a type of herpes virus caused by varicella-zoster virus. Approximately 90 percent of people who are contrary to the virus are under the age of ten. Most of the time is the use of acyclovir for falsepox necessary, because most healthy children can fight the virus without the help of external drugs. The condition is characterized by fever, which occurs with lesions filled with liquid on the face, body and scalp. These lesions are notorious, but USUALLY dries about five days after the onset of the state. This is usually only in patients with an already weakened immune system. InterrogationThe DEK is that patients who have a history of immunity problems will generally be recommended treatment such as acyclovir for chickenpox. Otherwise, it is unlikely that health patients would be recommended because most will start to recover within six days of the beginning of the condition.

Acyclovir is classified as an antiviral drug and can also be used to treat herpes, shingles and Epstein-Barr virus. In fact, the drug is activated by the cells of the virus, which are replicated and destroyed by common, healthy cells in this process. When used by acyclovir for smallpox, the drug is associated with a virus that attempts to use it instead of nucleoside, it usually requires propagation. The result is a reduction in the spread of the condition.

Studies to Acyklovir for Planná Pox had generally positive results. One large study took 815 patients who developed smallpox 24 hours before the attempt. These entities were randomly divided into DVOU groups, one of which received acyclovir and the other group got placebo. After the initial four -day observation period, 95 percent of patients receiving acyclovir for Planá pox have ceased to develop a rash. On a six -day mark of 20 percent of the Placeba group, the rash still developed.